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Abstract
Coagulation factor VIII and von Willebrand factor (VWF) are key proteins in procoagulant 
activation. Higher FVIII coagulant activity (FVIII:C) and VWF antigen (VWF:Ag) are risk factors 
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for cardiovascular disease and venous thromboembolism. Beyond associations with ABO blood 
group, genetic determinants of FVIII and VWF are not well understood, especially in non 
European-American populations. We performed a genetic association study of FVIII:C and 
VWF:Ag that assessed 50,000 gene-centric single nucleotide polymorphisms (SNPs) in 18,556 
European Americans (EAs) and 5,047 African Americans (AAs) from five population-based 
cohorts. Previously unreported associations for FVIII:C were identified in both AAs and EAs with 
KNG1 (most significantly associated SNP rs710446, Ile581Thr, P=5.10 × 10−7 in EAs and P=3.88 
× 10−3 in AAs) and VWF rs7962217 (Gly2705Arg, P=6.30 × 10−9 in EAs and P=2.98 × 10−2 in 
AAs). Significant associations for FVIII:C were also observed with F8/TMLHE region SNP 
rs12557310 in EAs (P=8.02 × 10−10), with VWF rs1800380 in AAs (P=5.62 × 10−11), and with 
MAT1A rs2236568 in AAs (P=1.69 × 10−6). We replicated previously reported associations of 
FVIII:C and VWF:Ag with the ABO blood group, VWF rs1063856 (Thr789Ala), rs216321 
(Ala852Gln), and VWF rs2229446 (Arg2185Gln). Findings from this study expand our 
understanding of genetic influences for FVIII:C and VWF:Ag in both EAs and AAs.
Introduction
Coagulation factor VIII (FVIII) and von Willebrand factor (VWF) provide critical functions 
in hemostasis. In the circulation, 95% of FVIII is bound to VWF as an inactive complex that 
stabilizes FVIII [1,2]. Activated FVIII, after its release from VWF, acts as a cofactor for 
factor IXa-mediated activation of factor X and the subsequent conversion of prothrombin to 
its active form, thrombin [1]. VWF, an adhesive glycoprotein, also promotes platelet 
adhesion and aggregation [3]. Levels of FVIII coagulant activity (FVIII:C) and VWF 
antigen (VWF:Ag) in the top 25% of the population distribution are risk factors for venous 
thromboembolism and arterial vascular events [3,4].
In family studies, a significant genetic contribution has been documented for variation in 
FVIII:C and VWF:Ag, with estimated heritability ranging between 0.31 and 0.75 [5–7]. 
Shared genetic effects of FVIII:C and VWF:Ag on their risk to thrombosis have also been 
documented [8]. There are few reports of candidate gene studies focused on the FVIII, VWF, 
and ABO structural genes [9–14] and two genome-wide association studies (GWAS) [15,16] 
for FVIII:C or VWF:Ag traits. The ABO locus is a major contributor to their levels 
[10,15,16] and ABO alleles are also associated with the risk of venous thrombosis [17–19]. 
The first GWAS study, which included both FVIII:C and VWF:Ag in individuals of 
European ancestry (EA), reported associations at additional loci including STXBP5, 
SCARA5, VWF, STAB2, STX2, TC2N, and CLEC4M. These loci, including ABO, explained 
only 10.0-12.8% of the variation in FVIII:C and VWF:Ag [15]. The second GWAS, for 
VWF:Ag based on two young and healthy cohorts of EA ancestry and mixed ancestry, 
respectively, confirmed the associations at ABO and VWF and identified a new linkage 
region at chromosome 2q12–2p13 [16]. Data from other ethnic populations, such as African 
Americans (AAs), are limited to one report that sequenced only coding regions of the VWF 
gene [14].
In this study, we investigated the associations of circulating levels of FVIII:C and VWF:Ag 
with single nucleotide polymorphisms (SNPs) on the gene-centric 50K SNP ITMAT-Broad-
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CARe (IBC) genotyping array. The CARe IBC chip was designed to include a greater SNP 
marker density, including more non-synonymous variants, for more than 2,000 
cardiovascular candidate regions, compared with the genome-wide arrays used in the 
published GWAS study [20]. The analyses were based upon 18,556 European Americans 
(EAs) and 5,047 AAs from five population-based cohorts in the Candidate Gene Association 
Resource (CARe) Consortium [21].
Material and Methods
Study population
This analysis included five participating cohorts in the CARe Consortium [21] that had 
assayed FVIII:C and/or VWF:Ag: the Atherosclerosis Risk in Communities (ARIC) study 
[22], the Coronary Artery Risk Development in Young Adults (CARDIA) study [23], the 
Cardiovascular Health Study (CHS) [24,25], the Framingham Heart Study (FHS) [26], and 
the Multi-Ethnic Study of Atherosclerosis (MESA) [27] (Table I). All participating 
institutions gave institutional review board approval for this study and all participants gave 
written informed consent. Details on the participating cohorts are provided in Supporting 
Information Methods.
Phenotype measurement
Plasma FVIII:C and/or VWF:Ag was measured in the entire cohort at baseline for ARIC 
(both FVIII:C and VWF:Ag) [28,29], CHS (FVIIIc) [30], and MESA (FVIIIc) [31]. In 
CARDIA, participants attending two field centers were measured at the years 5 and 7 exams 
for plasma FVIII:C and at the years 2, 5, and 7 exams for VWF:Ag [32]. Additionally, 
plasma VWF:Ag was measured in the FHS Offspring cohort during the fifth examination 
cycle [33] and in a random sample of 1,000 participants in MESA [31]. In each cohort, 
FVIII:C was measured using standard clinical clotting time-based assays and VWF:Ag was 
measured by ELISA or immunoturbidometric assays. Details on the laboratory assays are 
provided in Supporting Information Table SI. Information on clinical, demographic, 
lifestyle, and anthropometric characteristics were obtained in each cohort at the same visit as 
the measurements for FVIII:C and VWF:Ag.
Genotyping, imputation, and quality control
All samples were genotyped at the Broad Institute using the IBC Illumina iSELECT array 
[20]. The 50,000 SNPs on the IBC array are distributed across ∼2,100 genes selected to 
cover a range of cardiovascular, metabolic, lung, blood, sleep, and inflammatory pathways 
[20]. The SNP selection, designed to capture maximal genetic information specific to 
European and African ancestries excluding rare variants, was informed by the HapMap data 
and supplemented by the SeattleSNPs and Environmental Genome Project resequencing 
data [20]. All non-synonymous variants of minor allele frequency (MAF) > 0.01 were 
included to supplement tagging SNPs. Imputation to the phase 2 HapMap data at gene 
regions for un-genotyped SNPs was conducted using MACH 1.0.16 [34], with the CEU 
founders of the HapMap2 as the reference panel for the CARe EA samples and the 
combined CEU+YRI samples as the reference panel for the CARe AA samples. SNPs with 
imputation quality score < 0.6 were excluded. Details on genotyping, imputation, and 
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quality control (QC) in these five participating cohorts are provided in Supporting 
Information Methods.
Statistical analysis
Participants who were taking anticoagulants or had FVIII:C or VWF:Ag values more than 6 
standard deviations from the mean were excluded. Untransformed measurements for 
FVIII:C and VWF:Ag were regressed on age, sex, and study site (where appropriate) using 
linear regression models stratified by cohort and ethnic group to create cohort and ethnic-
specific residuals. These residuals were inverse normal transformed and used in genetic 
association analysis, performed separately for EAs and AAs within each study. In CARDIA, 
the residuals based on measurements of each exam year were averaged across years and the 
averaged values were used in the inverse normal transformation. The genetic analysis used 
an allele dosage for each SNP, assuming an additive genetic effect, and adjusted for the first 
10 principal components derived from EIGENSTRAT [35] to account for potential 
population stratification. For cohorts of unrelated individuals, a linear regression model was 
used with PLINK V 1.0.7 [36]; for the FHS family data, a linear mixed effects model was 
used to account for correlation between individuals due to family structure [37]. Ethnic-
specific results across studies were combined using a fixed effects, inverse variance-
weighted meta-analysis as implemented in METAL [38]. Genomic control correction was 
applied during the meta-analysis. SNPs with MAF-weighted sample size (MAF × N) < 10 or 
imputed SNPs with MAF < 1% were excluded from individual cohorts. The significance 
threshold was P < 2.0 × 10−6, to account for the effective number of independent tests [39]. 
Heterogeneity was assessed using the I2 inconsistency metric. To obtain clinically 
meaningful effect size estimates, association analyses were repeated for the most 
significantly associated SNPs with untransformed FVIII:C and VWF:Ag measurements. The 
proportion of variance explained by SNPs was based on the ARIC data, the largest study in 
the consortium, and calculated by subtraction of variance explained by non-SNP covariates 
from the total variance explained by all covariates in linear regression models.
Analysis of X chromosome SNPs
The analytical approach for X chromosome SNPs was similar to that described above for 
autosomal SNPs except as follows: for males, genotypes for SNPs on the X chromosome 
were coded as 0 or 2 [40]. In PLINK linear regression, sex was automatically adjusted for as 
a covariate for the analysis of X chromosome SNPs. The results from the PLINK analysis 
were highly consistent with those from an alternative approach in which males and females 
were analyzed separately in linear regression in SAS and meta-analyzed across cohort and 
gender groups. The percentage of variance explained by X chromosome SNPs (i.e., F8 
SNPs) was calculated by GCTA (genome-wide complex trait analysis) with full dosage 
compensation [41].
When multiple statistically significant SNPs clustered at a region, sequential conditional 
analyses were performed to adjust for the most significant SNP from each adjustment step 
until no other SNP attained significance. Since the association of ABO blood group with 
VWF:Ag and FVIII:C was known and the ABO locus was significant in this study, we used 
the following SNPs to tag the O, B, A2, and O2 groups in conditional analyses: rs529565 
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(tag for O in EA, r2=0.67), rs8176693 (for O in AA, r2=0.55), rs8176749 (one of the 
functional variants for B group), rs8176704 (for A2, r2=1 in both EA and AA), and 
rs512770 (the functional variant for O2) [42]. Linkage disequilibrium (LD) between SNPs, 
represented by r2, was used to evaluate the independence of associations from a region. The 
r2 statistics from the CEU sample of the HapMap phase 2 were used as a reference for the 
CARe EA data, while those from the combined African and African American samples of 
the HapMap phases 2 and 3 were used for the CARe AA data.
Results
The distributions of demographic variables, FVIII:C, and VWF:Ag in 18,556 EA and 5,047 
AA participants are shown in Table I. The race-specific quantile-quantile (Q-Q) plots for 
observed vs. expected –log10 P values for both traits are shown in Supporting Information 
Figs. S1-S4. There was little influence of population stratification on the data, as evidenced 
by inflation factors for FVIII:C and VWF:Ag of 1.06 and 1.01, respectively, in EAs, and 
0.97 and 1.00, respectively, in AAs. Table II presents the most significantly associated SNPs 
with FVIII:C and VWF:Ag in EAs and AAs.
Genetic associations in EAs
In EAs, 119 SNPs for FVIII:C and 140 SNPs for VWF:Ag exceeded the pre-specified 
significance threshold of P < 2 × 10−6. The significant SNP associations for FVIII:C 
clustered at 4 loci: KNG1 (kininogen 1) on chromosome 3q27; ABO on chromosome 
9q34.1-q34.2; VWF on chromosome 12p13.3; and F8/TMLHE (trimethyllysine hydroxylase, 
epsilon) on chromosome Xq28. The significant SNP associations for VWF:Ag clustered at 2 
loci, ABO and VWF.
At the KNG1 locus, 3 SNPs that are in high LD (r2=0.84–1.00) were associated with 
FVIII:C – rs698078 (P=4.26 × 10−7, Table II), rs710446 (coding, nonsynonymous, P=5.10 
× 10−7, Table II), and rs5030062 (P=1.81 × 10−6) (Fig. 1). The P values for the other two 
SNPs did not attain statistical significance after adjustment for rs710446 (P > 0.05). At the 
ABO locus, the strongest association for both FVIII:C and VWF:Ag was with rs529565 (P < 
1.0 × 10−199 for both FVIII:C and VWF:Ag, Table II). rs529565 is intronic to the ABO gene 
and tags the O blood group (r2=0.67 with the O group variant). Simultaneous adjustment for 
the SNPs that tag the ABO O, B, A2, and O1v/O2 groups abolished all the other ABO SNP 
associations for both traits.
At the VWF locus, three sets of independent SNP associations, spanning 24 SNPs, were 
identified for FVIII:C (Table II, Supporting Information Table SII). The three sets were led 
by rs1063856 (coding-nonsynonymous, Thr789Ala, P=5.84 × 10−12), rs7962217 (coding-
nonsynonymous, Gly2705Arg, P=6.30 × 10−9; P=4.03 × 10−8 after adjustment for 
rs1063856), and rs216321 (coding-nonsynonymous, Ala852Gln, P=6.30 × 10−9; P=4.03 × 
10−8 after adjustment for rs1063856 and rs7962217), respectively. The top variants 
rs1063856, rs7962217, and rs216321 are in low LD (r2=0.008–0.035) and are consistent 
with three independent sites of genetic contribution within a single gene to variation in 
FVIII:C. For VWF:Ag at the VWF locus, two sets of independent associations of 42 SNPs 
emerged (Table II, Supporting Information Table SIII), led by rs1063856 (P=1.06 × 10−19) 
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and rs216321 (P=1.71 × 10−17; P=6.36 × 10−12 after adjusting for rs1063856), respectively. 
Association plots are presented for FVIII:C (Fig. 2) and VWF:Ag (Supporting Information 
Fig. S5) in the VWF locus.
Interestingly, the second set of independent SNPs in VWF for FVIII:C, led by rs7962217, 
was not associated with VWF:Ag in either the meta-analysis of all cohorts (P=0.38 for 
rs7962217) or individual cohorts (e.g., in ARIC, P=0.75 for rs7962217).
On the X chromosome, one TMLHE SNP (rs12557310, P=8.02 × 10−10) and 4 SNPs from 
F8 (most significant SNP, rs2096362, P=1.88 × 10−9) were significantly associated with 
FVIII:C (Supporting Information Tables SIV, Supporting Information Fig. S6). rs12557310 
is the only SNP from the TMLHE gene that was genotyped. Of the 4 F8 SNPs, one is 
coding-nonsynonymous (rs1800291, P=9.74 × 10−7) and the remaining 3 SNPs (including 
the most significant, rs2096362) are intronic. There was weak to moderate LD between the 
TMLHE SNP rs12557310 and the four F8 SNPs (r2=0.08–0.31), with stronger LD among 
the four F8 SNPs (r2=0.20–1.00), as expected. Adjustment for rs1800291 only modestly 
attenuated the association at TMLHE (P=3.12 × 10−5 for rs12557310, Supporting 
Information Fig. S6). In contrast, adjusting for rs12557310 in TMLHE removed the majority 
of the association for the F8 SNPs (P=0.08–0.0028).
Of the associations identified above in EAs, those with the KNG1 locus, VWF (rs7962217 
and rs216321), and TMLHE (rs12557310) for FVIII:C have not been previously reported. 
The total variance explained by the significant and independent associated SNPs was 14.5% 
for FVIII:C (12.6% for autosomal SNPs and 1.9% for X chromosome SNPs) and 15.6% for 
VWF:Ag.
Genetic associations in AAs
In African Americans, 85 SNPs were significantly associated with FVIII:C and 76 SNPs 
were associated with VWF:Ag. The SNPs were located in three loci for FVIII:C – ABO, 
MAT1A (methionine adenosyltransferase I, alpha, chromosome 10q22), and VWF. In 
contrast to FVIII:C, the SNP associations for VWF:Ag were located in ABO and VWF.
In the ABO locus, 68 SNPs were significantly associated with FVIII:C and/or VWF:Ag. The 
most significantly associated SNP for both traits was rs8176693 (P=2.51 × 10−114 for 
FVIII:C and P=1.66 × 10−89 for VWF:Ag; Table II). rs8176693 is intronic in ABO and a tag 
for the O blood group (r2=0.55). Adjustment for SNPs that tag the O, B, A2, and O1v/O2 
groups did not abolish all the other ABO associations for either trait, with a few intergenic 
and intronic SNPs remaining significant (data not shown). These remaining SNP 
associations could be attributable to incomplete adjustment, as a result of relatively poor 
imputation quality for the O proxy SNP rs8176693 (0.65–0.78), as well as modest LD 
between rs8176693 and the O functional variant in African Americans (r2=0.55). The 
remaining SNP associations at the ABO locus were not further investigated.
At the MAT1A locus, one intronic variant (rs2236568) was significantly associated with 
FVIII:C (P=1.69 × 10−6) while other SNPs showed similar, but weaker, association with 
FVIII:C (Supporting Information Figures).
Tang et al. Page 6













At the VWF locus, 16 and 8 SNPs exceeded the P < 2 × 10−6 threshold in their associations 
with FVIII:C and VWF:Ag (Supporting Information Tables SV and SVI), respectively. The 
significant SNPs for FVIII:C included three independent sets, led by rs2229446 (coding-
nonsynonymous, Arg2185Gln, P=1.95 × 10−20), rs1800380 (coding-synonymous, P=5.62 × 
10−11; P=7.60 × 10−10 after conditioning on rs2229446), and rs4764482 (intronic, P=8.12 × 
10−8; P=9.57 × 10−8 after 2nd conditional analysis). The significant SNPs for VWF:Ag at 
VWF included two independent sets and were led by rs2229446 (P=1.13 × 10−16) and 
rs1063856 (P=1.72 × 10−10; P=5.14 × 10−12 after conditioning on rs2229446). There is low 
LD among the leading variants rs2229446, rs1800380, and rs1063856 (r2=0.004–0.02). 
rs1063856, the second top independent SNP for VWF:Ag in AAs, is tagged by the 3rd 
independent set for FVIII:C (r2=0.54–0.16, Supporting Information Results). Association 
plots for FVIII:C and VWF:Ag at the VWF region in AAs are presented in Supporting 
Information Figures.
Of the associations in AAs, those with the MAT1A locus and VWF rs1800380 for FVIII:C 
have not been previously reported. The total variance explained by the significant and 
independent SNPs was 11.0% for FVIII:C and 13.2% for VWF:Ag.
Details on the conditional analysis results can be found in Supporting Information Results, 
and association plots for other loci in Supporting Information Figures. There was no 
evidence of significant heterogeneity across studies for most of the associated SNPs, with 
the exception of one between ABO rs529565 with VWF:Ag in EAs (P=1.92 × 10−8); 
however, the effect sizes were not substantially different across studies (data not shown).
Cross-ethnic comparison
The most associated SNPs for FVIII:C and VWF:Ag among EAs and AAs were compared 
in Table III. Most of the significantly associated SNPs identified in either EAs or AAs were 
replicated in the other ethnic group, with similar direction of association and nominal p < 
0.05. An exception was noted for FVIII:C with the TMLHE/F8 SNPs in AAs and the 
MAT1A SNP association in EAs. The strongest SNP association for FVIII:C at F8 in AAs 
was different—rs5945270 (intronic, MAF=0.006, P=0.03). In both African/African 
American and European samples of the HapMap Project, there is low LD between the non-
overlapping VWF SNPs identified in our EA (rs7962217 and rs216321) and AA (rs2229446 
and rs1800380) populations (Supporting Information Tables SVIIa and SVIIb).
Discussion
We investigated genetic determinants of FVIII:C and VWF:Ag levels based on 50,000 SNPs 
from a cardiovascular gene-centric chip (supplemented by imputation data) in 18,556 EAs 
and 5,047 AAs from five population-based cohort studies in the USA. We identified novel 
loci, KNG1 and TMLHE in EAs, and novel associations in VWF (rs7962217 in EAs and 
rs1800380 in AAs) that have not been reported previously for FVIII:C and VWF:Ag. The 
newly identified associations with KNG1 and VWF SNPs were replicated across our ethnic 
populations. Of note, the locus represented by VWF rs7962217 was specific to FVIII:C, with 
no significant association for VWF:Ag. We also extended the association of VWF rs216321 
with VWF:Ag previously reported in EAs [43,44] to FVIII:C in both EA and AA 
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populations. Finally we confirmed previously reported associations of FVIII:C and VWF:Ag 
levels with VWF rs1063856 from EA and AA populations [13–15,43–46], VWF rs2229446 
from an AA population [14], and the ABO locus [10] from a European population.
At the KNG1 locus, the most associated SNP, rs710446, is in exon 10 of kininogen isoform 
1 (high molecular weight kininogen, HMWK) and codes for an Ile to Thr substitution at 
amino acid 581, predicted to be involved in splicing regulation [47]. KNG1 has not been 
previously associated with FVIII:C. HMWK is a cofactor for activation of kallikrein and 
factors XI and XII. Defects in KNG1 are the cause of HMWK deficiency (MIM #228960), 
an autosomal recessive disorder. rs710446 has been associated with the activated partial 
thromboplastin time (aPTT), FXI, and VTE risk in EA populations [48–52]. The aPTT is 
highly correlated with FVIII:C and is a global coagulation test that reflects the interacting 
effects of factors in the classical intrinsic (FXII, FXI, FIX and FVIII) and common 
coagulation cascades as well as contact activation [53]. There are two possible 
interpretations of the identified association of KNG1 with FVIII:C. The first is that the 
association was observed by virtue of the aPTT reflecting HMWK levels (in part) and that 
FVIII:C is measured using an aPTT-based assay; the second is that this association reflects 
an unknown functional link between HWMK and FVIII. Further investigations, including 
functional assays for HMWK levels, are needed to understand the underlying mechanisms 
for this association.
Because VWF serves as a carrier for FVIII, we expected overlapping genetic associations 
for these two phenotypes at ABO and VWF. However, we observed discrepant results for 
VWF rs7962217; this SNP was only associated with FVIII:C, indicating that the locus 
tagged by VWF rs7962217 influences FVIII:C through other pathways than VWF:Ag levels. 
VWF rs7962217 is located in exon 50 of the VWF gene and codes for Gly to Arg substitution 
at amino acid 2705 (G2705R), which is predicted to be deleterious, affecting a splicing site 
[47,54]. Exon 50 is within the carboxy-terminus (CK) domain of the VWF protein. The CK 
domain is crucial for the dimerization of the VWF subunit and mutations in this domain 
have been identified in type 2A von Willebrand Disease (VWD2A) [55], thought to be 
associated with synthesis or proteolysis of VWF multimers. Future studies are needed to 
investigate the mechanisms by which this VWF variant influences FVIII:C level, including 
the possibility of mediation through VWF dimerization on the interaction of VWF with 
FVIII.
We detected significant associations at the F8/TMLHE region for FVIII:C in EAs, in 
contrast to the published GWAS study [15] that observed no significant associations in the 
F8 locus. In that GWAS, imputation data for the X chromosome were not available in two 
of the four studies. In our study, the F8 SNPs on the IBC chips were selected as tag SNPs to 
provide a greater LD coverage than genome-wide arrays, enabling a more comprehensive 
investigation of F8 effects on phenotypes. Of the four F8 SNPs that were significantly 
associated with FVIII:C in our study, rs1800291 (D1241E) has been previously associated 
with FVIII:C in two studies of European populations [9,11]. In our study, the effect size of 
rs1800291 was weaker compared to the other three F8 SNPs and TMLHE rs12557310. 
Adjustment for rs1800291 only modestly reduced the significance of association for the 
other SNPs, in contrast to more substantial reduction in significance after adjusting for 
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rs12557310. A previously published report of the ARIC data identified eight F8 intronic 
SNPs associated with FVIII:C or FVIII:C/VWF:Ag in EAs [56]. There is weak to modest 
LD between rs12557310 and the eight reported SNPs (r2=0.11–0.36), in contrast to stronger 
LD between rs1800291 and the eight SNPs (r2=0.14–0.67). Therefore, it is possible that the 
associations we observed at the TMLHE/F8 locus are attributable to a different underlying 
F8 variant than those reflected by rs1800291 or the eight F8 SNPs. TMLHE encodes 
trimethyllysine dioxygenase, whose relevance to coagulation pathways is currently 
unknown. It was noted that the associations at the TMLHE/F8 region were not observed in 
AAs of our study. This discrepancy could be due to different LD between the two 
populations as well as interactions by other ethnicity-related factors.
The association between FVIII:C and MAT1A SNPs has not been previously reported in any 
ethnic populations. MAT1A encodes hepatic methionine adenosyltransferase I/III, which is 
responsible for the synthesis of S-adenosylmethionine (SAM). SAM donates methyl groups 
for most biological methylations including the generation of homocysteine [57], and 
hyperhomocysteinemia is a modest risk factor for VTE [57]. The MAT1A SNP associations 
detected with FVIII:C should be confirmed in independent populations, given the lack of 
replication for this association in the EAs in this study.
Recently, Johnsen et al. [14] reported associations of FVIII:C and VWF:Ag with 
nonsynonymous variants in VWF in four AA populations, discovered by exome sequencing 
in the NHLBI Exome Sequencing Project; three of the cohorts overlapped with those in this 
study (ARIC, CARDIA and MESA). In that study [14], six VWF SNPs were independently 
associated with VWF:Ag and/or FVIII:C levels: rs1063856, rs57950734, rs11063988, 
rs149424724, rs76342212 (i.e., rs2229446), and rs61750625. Our study confirmed the 
findings for rs1063856 and extended the association for rs2229446 to EA populations. Of 
the other three VWF SNPs identified in our study (rs7962217, rs216321, and rs1800380), 
Johnsen et al. [14] analyzed only rs7962217 but did not find significant association 
(P=0.25–0.55). rs7962217 was primarily identified in EAs of our study (P=6.30 × 10−9) 
with nominal significance in AAs (P=0.03).
While AA populations in the two studies largely overlapped, all participants in our study 
were genotyped for rs7962217, in contrast to 595 participants in the Johnsen et al. [14] study 
being sequenced and the rest imputed for all VWF variants. The difference in genotyping 
coverage might explain the discrepant significance for this SNP in AAs. Between our VWF 
SNPs (rs216321 and rs1800380) and the other four SNPs of that study, LD information in 
HapMap is only available for rs61750625, which was not in LD with our variants (r2=0). In 
the pooled ARIC IBC data with the VWF sequencing and imputation data from Johnsen et 
al. [14], LD between our SNPs (rs216321 and rs1800380) and the other three of that study 
[14] (rs57950734, rs11063988, rs149424724) approached zero for most pairs (r2 < 0.05), 
with the highest between rs1800380 and rs11063988 (r2=0.11).
Strengths and limitations
The CARe IBC custom genotyping array provides a great advantage for this study because a 
majority of the genes relevant to the coagulation pathway were included and the array has 
better LD coverage, including more non-synonymous variants, than in the previously 
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published GWAS [15]. While the EA populations in this study partially overlapped with 
those in the published GWAS [15], we included new populations (CARDIA and MESA) 
which, in combination with the advantages of the CARe IBC array and sequential 
conditional analysis, provided additional information beyond the published GWAS study. 
The increased percentage of variance explained by the most associated, independent SNPs 
for both traits compared to the previously published GWAS [15] demonstrates the value of 
the gene-centric genotyping array and contribution of this study to the understanding of 
genetic basis of both traits. Also, the analysis of AA data in our study represents the largest 
of this kind and provided an opportunity to compare associations across the two ethnic 
groups. However, there are limitations to our study. The assays for FVIII:C and VWF:Ag 
were conducted in each individual study, which may have added variation in the levels of 
these two measurements across studies. This variation should have a minimal influence on 
the genetic contribution to phenotypes, as the genetic association analysis was conducted 
within each study to correlate the rank of the phenotype measurements with the rank of 
genotype allele dosage, and the results were meta-analyzed across studies. Also, our study 
investigated common and low-frequency SNPs included on the pre-defined genotyping 
arrays and might miss rare and new SNPs that were unknown at the time of array design, or 
novel loci that could be detected with a denser genome-wide array and imputation.
In conclusion, using a gene-centric approach, we identified and replicated new associations 
for FVIII:C at KNG1 as well as with SNPs in VWF that have not been reported previously. 
With the availability of both EA and AA samples, we were able to delineate the similarities 
and differences in the genetic associations between the two ethnic groups. Findings from 
this study expand our understanding of genetic determinants for FVIII:C and VWF:Ag and 
will guide future efforts to examine the contributions of the newly identified variants to the 
risk of thrombosis in EA and AA populations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Regional association plot at chromosome 3q27 region for FVIII:C in EAs. The horizontal 
line indicates the pre-specified significance threshold of P = 2.0 × 10−6. The top SNP is 
shown by the blue triangle and labeled. The colors of the remaining SNPs reflect the r2 with 
the top SNP based on the HapMap CEU data with the following color scheme: r2≥0.8—red, 
0.5≤r2 < 0.8—orange, 0.2≤r2 < 0.5—yellow, r2 < 0.2—white. The light blue line represents 
the recombination rate (the y axis at right side) based on the data from the HapMap CEU, 
YRI and JPT1CHB populations. Gene annotations are shown along the x axis.
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Regional association plot at chromosome 12p13.3 region for FVIII:C in EAs. The 1st and 
2nd top independent SNPs are shown by the blue triangle and labeled.
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